Human Pathology
Volume 41, Issue 2 , Pages 271-280 , February 2010

CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas

  • Robert F. Luo, MD, MPH

      Affiliations

    • Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
    • ,
  • Shuchun Zhao, MS

      Affiliations

    • Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
    • ,
  • Robert Tibshirani, PhD

      Affiliations

    • Department of Health Research and Policy and Statistics, Stanford University School of Medicine, Stanford, CA 94305, USA
    • ,
  • June H. Myklebust, PhD

      Affiliations

    • Division of Oncology, Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    • ,
  • Mrinmoy Sanyal, PhD

      Affiliations

    • Division of Oncology, Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    • ,
  • Rosemary Fernandez

      Affiliations

    • Division of Oncology, Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    • ,
  • Dita Gratzinger, MD, PhD

      Affiliations

    • Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
    • ,
  • Robert J. Marinelli, PhD

      Affiliations

    • Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
    • ,
  • Zhi Shun Lu, MS

      Affiliations

    • Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
    • ,
  • Anna Wong, MD

      Affiliations

    • Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
    • ,
  • Ronald Levy, MD

      Affiliations

    • Division of Oncology, Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    • ,
  • Shoshana Levy, PhD

      Affiliations

    • Division of Oncology, Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    • These authors contributed equally.
    • ,
  • Yasodha Natkunam, MD, PhD

      Affiliations

    • Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
    • Corresponding Author InformationCorresponding author.
    • These authors contributed equally.

Received 8 May 2009 ,Revised 28 July 2009 ,Accepted 30 July 2009.

References 

  1. Levy S, Shoham T. The tetraspanin web modulates immune-signaling complexes. Nat Rev Immunol. 2005;5:136–148
  2. Shoham T, Rajapaksa R, Boucheix C, Tedder TF, et al. The tetraspanin CD81 regulates the expression of CD19 during B cell development in a postendoplasmic reticulum compartment. J Immunol. 2003;171:4062–4072
  3. Tedder TF, Inaoki M, Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity. 1997;6:107–118
  4. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science. 1998;282:938–941
  5. Weng WK, Levy S. Hepatitis C virus (HCV) and lymphomagenesis. Leuk Lymphoma. 2003;44:1113–1120
  6. Rosa D, Saletti G, De Gregorio E, et al. Activation of naïve B lymphocytes via CD81, a pathogenic mechanism for hepatitis C virus–associated B lymphocyte disorders. Proc Natl Acad Sci USA. 2005;102:18544–18549
  7. Machida K, Cheng KT, Pavio N, Sung VM, Lai MM. Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells. J Virol. 2005;79:8079–8089
  8. Serra A, Nuti S, Tavarini S, et al. Coligation of the hepatitis C virus receptor CD81 with CD28 primes naïve T lymphocytes to acquire type 2 effector function. J Immunol. 2008;181:174–185
  9. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511
  10. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68–74
  11. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105:1851–1861
  12. Rosenwald A, Wright G, Chan WC, et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large B cell lymphoma. N Engl J Med. 2002;346:1937–1947
  13. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350:1828–1837
  14. Malumbres R, Chen J, Tibshirani R, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood. 2008;111:5509–5514
  15. Natkunam Y, Zhao S, Mason DY, et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B cell lymphomas. Blood. 2007;109:1636–1642
  16. Natkunam Y, Farinha P, Hsi ED, et al. LMO2 protein expression predicts survival in patients with diffuse large B cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol. 2008;26:447–454
  17. Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol. 2004;2:E108
  18. Hummel M, Bentink S, Berger H, et al. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419–2430
  19. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B cell lymphoma. J Clin Oncol. 2006;24:995–1007
  20. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon: IARC Press; 2008;
  21. Stokke T, Galteland E, Holte H, et al. Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B cell non-Hodgkin's lymphoma. Int J Cancer. 2000;89:313–324
  22. Natkunam Y, Lossos IS, Taidi B, et al. Expression of the human germinal center–associated lymphoma (HGAL) protein, a new marker of germinal center B cell derivation. Blood. 2005;105:3979–3986
  23. Mason DY, Micklem K, Jones M. Double immunofluorescence labelling of routinely processed paraffin sections. J Pathol. 2000;191:452–461
  24. Marinelli RJ, Montgomery K, Liu CL, et al. The Stanford tissue microarray database. Nucleic Acids Res. 2008;36:D871–D877
  25. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282
  26. Natkunam Y, Warnke RA, Montgomery K, Falini B, van De Rijn M. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol. 2001;14:686–694
  27. Mittelbrunn M, Yáñez-Mó M, Sancho D, Ursa A, Sánchez-Madrid F. Cutting edge: dynamic redistribution of tetraspanin CD81 at the central zone of the immune synapse in both T lymphocytes and APC. J Immunol. 2002;15:6691–6695
  28. Viswanatha DS, Dogan A. Hepatitis C virus and lymphoma. J Clin Pathol. 2007;60:1378–1383
  29. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med. 2002;346:235–242
  30. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B cell lymphoma. J Clin Oncol. 2006;24:3121–3127
  31. Pfreundschuh M, Trümper L, Osterborg A, et al. MabThera International Trial Group CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) group. Lancet Oncol. 2006;7:379–391
  32. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–5033

☆ Support: This work was partly funded by NIH CA34233, CA33399, and the Leukemia and Lymphoma Society SCORE grant. RL is an American Cancer Society Clinical Research Professor and JHM is a Norwegian Cancer Society Fellow.

PII: S0046-8177(09)00285-8

doi: 10.1016/j.humpath.2009.07.022

Human Pathology
Volume 41, Issue 2 , Pages 271-280 , February 2010

Article Tools

* Image Usage & Resolution